

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2700582

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THE UNIVERSITY OF BRISTOL	03/16/2006
RECEIVING PARTY DATA	
Name:	TRIDENT PHARMACEUTICALS, INC.
Street Address:	184 HIGH STREET, 4TH FLOOR
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02110
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13745082
CORRESPONDENCE DATA	
Fax Number:	
Phone:	617-542-6000
Email:	grdenningham@mintz.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	SHOVON ASHRAF
Address Line 1:	ONE FINANCIAL CENTER
Address Line 2:	MINTZ LEVIN
Address Line 4:	BOSTON, MASSACHUSETTS 02111
ATTORNEY DOCKET NUMBER:	34407-502C02US
NAME OF SUBMITTER:	SHOVON ASHRAF
Signature:	/Shovon Ashraf/
Date:	01/28/2014

Total Attachments: 4

source=34407-502C02US- Trident Pharmaceuticals, Inc. Assignment#page1.tif

source=34407-502C02US- Trident Pharmaceuticals, Inc. Assignment#page2.tif

source=34407-502C02US- Trident Pharmaceuticals, Inc. Assignment#page3.tif

source=34407-502C02US- Trident Pharmaceuticals, Inc. Assignment#page4.tif

Express Mail Label No.:
Date of Deposit:

Attorney Docket No.: 34407-501, -502, -503

ASSIGNMENT

The University of Bristol, an entity having offices at Senate House, Tyndall Avenue, Clifton, Bristol BS8 1TH, Great Britain ("ASSIGNOR"), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to Trident Pharmaceuticals, Inc., a Delaware corporation having principal offices at 75 State Street, Boston, MA 02109, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE: (1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations, continuations-in-part, and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in its name as the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations, extensions, continuations, continuations-in-part, and divisions thereof and any substitute applications therefor, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

ASSIGNOR hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, sale and transfer not been made.

ASSIGNOR agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

ASSIGNOR further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do that necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNOR hereby covenants that it has obtained full right to convey the entire interests listed in Schedule A by virtue of prior assignments, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

15-MAR-2006 10:53 From:

0117.9296393

To: Harrison Foerster B.318

ASSIGNOR further covenants that ASSIGNOR will, upon its request, be provided promptly with all pertinent files and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNOR or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

For The University of Bristol

Date:

[Signature]
Signature of: WILLIAM LEWIS
Title: DEPUTY FINANCE DIRECTOR
The University of Bristol

IN WITNESS WHEREOF, I hereto set hand

IN WITNESS WHEREOF, I hereto set hand

[Signature]
Signature of witness

[Signature]
Signature of witness

JANISSE J. COOKE
Name of witness

WEL MANSOUR
Name of witness

this 16 day of March 2006
Date of signing

this 16 day of March 2006
Date of signing

For Trident Pharmaceuticals Inc

[Signature]
Signature of: ROBIN BROWN
Title: DIRECTOR
Trident Pharmaceuticals Inc.

Signature Page for Assignments

Attorney Docket No.: 34407-501, -502, -503

SCHEDULE A

Title	Stage/Territory	Application and/or Patent No.	Reel/Frame No(s).
Therapeutic Agents and autoimmune diseases	PCT	PCT/GB96/01614	
	Australia	724516	
	Canada	2225788	
	China	96196258.5	
	Czech Republic	PV 12-98	
	Europe	EP 0841939	
	Hong Kong	HK 1006496	
	Hungary	224248	
	Japan	9-504927	
	Korea (South)	0452000	
	Mexico	9800241	
	Norway	319747	
	New Zealand	311762	
	Poland	187266	
	Russia	98101907	
	Singapore	50173	
	USA	08/999458; US 6,287,563	014066/0524; 014484/0401
US-CIP	09/867,914	014070/0650	
US-CIP - Div 1	10/240,134	see 014070/0650	
Agent for treating allergic or hypersensitivity condition	PCT	PCT/GB99/00070	
	Australia	762478	
	Canada	2,317,443	
	Europe	99900567.1	
	Japan	2000-527265	
	New Zealand	526218	
	USA	09/600,060	014070/0450
Vaccine	PCT	PCT/GB99/01461	
	Australia	2003261492	
	Canada	2331832	
	China	99808403.4	
	Czech Republic	PV 2000-4147	
	Eurasia	004794	
	Europe	99922284.7	
	Hungary	P 0104842	
	Israel	139467	
	India	IN/PCT/2000,00589/MUM	
	India	00353/MUMNP/2004 - a divisional application from	

Title	Stage/Territory	Application and/or Patent No.	Reel/Frame No(s).
		IN/PCT/2000,00589/MUM	
	Japan	2000-547996	
	Korea	2000-7012486	
	Mexico	010934	
	New Zealand	507911	
	Norway	20005599	
	Poland	P344519	
	Singapore	77072	
	South Africa	2000/6160	
	Ukraine	2000127088/M	
	USA	09/674,935	014273/0231

TRA.2128287v.1